Cardiology

Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.

Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.

Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.

Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.

Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data. 

Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.

Fish oil supplementation may be associated with lower all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events.

A new study found several shortcomings in blood pressure management.

The differences between antihypertension medication classes were generally small and nuanced in terms of their effect on reducing cardiovascular risks.

A secondary analysis presented at the American Stroke Association’s International Stroke Conference 2020 confirmed the safety of apixaban treatment.

Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.

Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.

A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.

SGLT2 inhibitor therapy provided protective effects from cardiovascular (CV) events in patients with type 2 diabetes with or without established CV disease.

Amlodipine lowered the risk of gout when compared with 2 other antihypertensive medications.

Ticagrelor (Brilinta, AstraZeneca) reduced the risk of stroke and death when taken with aspirin compared with aspirin alone.

Administration time for warfarin did not affect the stability of the drug’s anticoagulation effect, a new study showed. 

The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.

Individuals with a history of heart disease may be at an increased risk of developing kidney failure.

Are the benefits of lowering systolic blood pressure to less than 130 mm Hg the same for those aged 80 years and older as they are for younger patients?

AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.

A new study examined diabetes as an independent predictor of heart failure. 

The approvals were granted to generic apixaban applications from Micro Labs Limited and Mylan Pharmaceuticals Inc.

Invasive methods did not perform better than drug treatment in patients with stable ischemic heart disease

Officials with the FDA have approved a new indication and label expansion for icosapent ethyl (Vascepa, Amarin).